JP2020511529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511529A5 JP2020511529A5 JP2019568594A JP2019568594A JP2020511529A5 JP 2020511529 A5 JP2020511529 A5 JP 2020511529A5 JP 2019568594 A JP2019568594 A JP 2019568594A JP 2019568594 A JP2019568594 A JP 2019568594A JP 2020511529 A5 JP2020511529 A5 JP 2020511529A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- stimulus
- vector
- cell
- payload
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023139792A JP2023164900A (ja) | 2017-03-03 | 2023-08-30 | 免疫療法のためのｃｄ１９組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762466601P | 2017-03-03 | 2017-03-03 | |
| US62/466,601 | 2017-03-03 | ||
| US201762484052P | 2017-04-11 | 2017-04-11 | |
| US62/484,052 | 2017-04-11 | ||
| PCT/US2018/020741 WO2018161017A1 (en) | 2017-03-03 | 2018-03-02 | Cd19 compositions and methods for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023139792A Division JP2023164900A (ja) | 2017-03-03 | 2023-08-30 | 免疫療法のためのｃｄ１９組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511529A JP2020511529A (ja) | 2020-04-16 |
| JP2020511529A5 true JP2020511529A5 (zh) | 2021-04-15 |
| JP7341900B2 JP7341900B2 (ja) | 2023-09-11 |
Family
ID=63371272
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568594A Active JP7341900B2 (ja) | 2017-03-03 | 2018-03-02 | 免疫療法のためのｃｄ１９組成物及び方法 |
| JP2023139792A Pending JP2023164900A (ja) | 2017-03-03 | 2023-08-30 | 免疫療法のためのｃｄ１９組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023139792A Pending JP2023164900A (ja) | 2017-03-03 | 2023-08-30 | 免疫療法のためのｃｄ１９組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3589646A4 (zh) |
| JP (2) | JP7341900B2 (zh) |
| KR (1) | KR20200010181A (zh) |
| CN (1) | CN110831961B (zh) |
| AU (2) | AU2018227583B2 (zh) |
| CA (1) | CA3055202A1 (zh) |
| SG (2) | SG11201907922PA (zh) |
| WO (1) | WO2018161017A1 (zh) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CN111107866A (zh) | 2017-06-12 | 2020-05-05 | 黑曜石疗法公司 | 用于免疫疗法的pde5组合物和方法 |
| WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
| AU2018385756A1 (en) * | 2017-12-15 | 2020-07-09 | Aleta Biotherapeutics Inc. | CD19 variants |
| WO2020068631A1 (en) * | 2018-09-24 | 2020-04-02 | Merck Sharp & Dohme Corp. | Expression vectors for eukaryotic expression systems |
| KR102520488B1 (ko) | 2018-11-06 | 2023-04-10 | 난트퀘스트, 인크. | 키메라 항원 수용체-변형된 nk-92 세포(chimeric antigen receptor-modified nk-92 cells) |
| US12109238B2 (en) | 2018-11-06 | 2024-10-08 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
| EP4063510A1 (en) * | 2018-11-07 | 2022-09-28 | Akouos, Inc. | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
| EP3894011A1 (en) * | 2018-12-11 | 2021-10-20 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| CN116479022A (zh) * | 2018-12-12 | 2023-07-25 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| IL283734B1 (en) | 2018-12-12 | 2024-11-01 | Kite Pharma Inc | Chimeric antigen receptors and CAR-T cells and methods of use |
| US20220144948A1 (en) * | 2019-01-29 | 2022-05-12 | Shanghai Jiao Tong University | Chimeric antigen receptor and use thereof |
| WO2020172643A2 (en) * | 2019-02-21 | 2020-08-27 | Luk John M | Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same |
| US12006345B2 (en) | 2019-02-21 | 2024-06-11 | Xencor, Inc. | Untargeted and targeted IL-10 Fc-fusion proteins |
| US20220144917A1 (en) | 2019-03-01 | 2022-05-12 | Universität Für Bodenkultur Wien | Stabilized extracellular domain of cd19 |
| SG11202109057XA (en) * | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| KR20210148106A (ko) * | 2019-03-08 | 2021-12-07 | 옵시디안 테라퓨틱스, 인크. | 조정 가능한 조절을 위한 cd40l 조성물 및 방법 |
| EP3935159A1 (en) * | 2019-03-08 | 2022-01-12 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| PE20212369A1 (es) * | 2019-04-26 | 2021-12-21 | Allogene Therapeutics Inc | Receptores de antigenos quimericos resistentes a rituximab y usos de estos |
| CN110079504A (zh) * | 2019-05-06 | 2019-08-02 | 山东大学第二医院 | 一种含有不稳定结构域的car-t细胞及其制备方法和调节car-t细胞功能方法 |
| CN110075275B (zh) * | 2019-05-15 | 2023-03-24 | 苏州大学 | IL-36β的应用 |
| JP2022537670A (ja) * | 2019-06-12 | 2022-08-29 | オブシディアン セラピューティクス， インコーポレイテッド | Ｃａ２の組成物および調整可能な制御方法 |
| CN110818803B (zh) * | 2019-07-24 | 2023-01-03 | 浙江启新生物技术有限公司 | 分泌表达il15ra-il15融合蛋白、ccl21趋化因子的嵌合抗原受体-t细胞及应用 |
| CN114641307A (zh) * | 2019-08-19 | 2022-06-17 | 艾佩斯瑞生物制药公司 | 抗cd19抗体及其用途 |
| EP4021464A4 (en) * | 2019-08-27 | 2024-01-03 | The Trustees of The University of Pennsylvania | SYNTHETIC CARS FOR TREATING IL13Ra2 POSITIVE HUMAN OR CANINE TUMORS |
| WO2021040736A1 (en) | 2019-08-30 | 2021-03-04 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| US20220348937A1 (en) * | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021072312A1 (en) * | 2019-10-11 | 2021-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting cd13 and tim-3 with car t cells to treat acute myeloid leukemia |
| CA3173981A1 (en) * | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
| US20230265390A1 (en) * | 2020-09-02 | 2023-08-24 | Nkarta, Inc. | Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof |
| EP4209593A4 (en) * | 2020-09-04 | 2024-10-09 | Heartseed Inc | IPS CELL QUALITY IMPROVING AGENT, METHOD FOR PRODUCING IPS CELLS, IPS CELLS, AND COMPOSITION FOR PRODUCING IPS CELLS |
| WO2022109443A1 (en) * | 2020-11-23 | 2022-05-27 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
| CN112795543B (zh) * | 2021-02-04 | 2022-09-27 | 华中农业大学 | 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用 |
| CN113403274B (zh) * | 2021-06-28 | 2023-11-10 | 上海睿臻迈生物医疗科技有限公司 | 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用 |
| CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
| CN114129718B (zh) * | 2021-10-19 | 2024-05-03 | 华东师范大学 | 一种用于体内自组装car-t的纳米递送系统及其制备方法和应用 |
| CN114558126B (zh) * | 2021-11-04 | 2024-11-08 | 苏州大学附属第一医院 | 序贯输注cd19 car-t和bcma car-t细胞在急性白血病患者免疫介导血小板输注无效中的联合应用 |
| CN116789822A (zh) * | 2022-03-18 | 2023-09-22 | 广东东阳光药业股份有限公司 | Claudin18.2人源化抗体及其应用 |
| WO2024189583A1 (en) * | 2023-03-15 | 2024-09-19 | Kyoto Prefectural Public University Corporation | Peptide expression constructs and uses thereof |
| CN116516007B (zh) * | 2023-04-18 | 2024-01-19 | 华中科技大学同济医学院附属协和医院 | Cd19表达的检测方法 |
| CN116536375B (zh) * | 2023-06-28 | 2023-11-10 | 北京大学深圳研究生院 | merocyclophanes类化合物的化学-酶法合成方法及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2216342B1 (en) * | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| KR100787393B1 (ko) * | 2006-03-23 | 2007-12-21 | 학교법인 한림대학교 | 세포 도입성 ｆｋ506 결합 단백질의 융합 단백질 |
| US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| US8530636B2 (en) * | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
| LT2649086T (lt) * | 2010-12-09 | 2017-11-10 | The Trustees Of The University Of Pennsylvania | Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui |
| BR112014008849A2 (pt) * | 2011-10-20 | 2017-09-12 | Us Health | receptores quiméricos de antígeno anti-cd22 |
| US9846162B2 (en) * | 2012-05-14 | 2017-12-19 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
| WO2014152932A1 (en) * | 2013-03-14 | 2014-09-25 | Board Of Regents, The University Of Texas System | Mirna for treating cancer and for use with adoptive immunotherapies |
| DK2997134T3 (da) * | 2013-05-14 | 2020-09-28 | Univ Texas | Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler |
| JP6684215B2 (ja) * | 2013-08-28 | 2020-04-22 | ピーシーアイ バイオテック エイエス | 予防接種用化合物および免疫化用化合物、ならびに予防接種方法および免疫化方法 |
| EP3057994B1 (en) * | 2013-10-15 | 2020-09-23 | The Scripps Research Institute | Peptidic chimeric antigen receptor t cell switches and uses thereof |
| US11382963B2 (en) * | 2015-01-12 | 2022-07-12 | Pieris Pharmaceuticals Gmbh | Engineered T cells and uses therefor |
| WO2016134284A1 (en) * | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| US11446398B2 (en) * | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN117959417A (zh) * | 2016-07-28 | 2024-05-03 | 诺华股份有限公司 | 嵌合抗原受体和pd-1抑制剂的组合疗法 |
| CN111107866A (zh) * | 2017-06-12 | 2020-05-05 | 黑曜石疗法公司 | 用于免疫疗法的pde5组合物和方法 |
-
2018
- 2018-03-02 JP JP2019568594A patent/JP7341900B2/ja active Active
- 2018-03-02 KR KR1020197029002A patent/KR20200010181A/ko active IP Right Grant
- 2018-03-02 AU AU2018227583A patent/AU2018227583B2/en active Active
- 2018-03-02 WO PCT/US2018/020741 patent/WO2018161017A1/en unknown
- 2018-03-02 CA CA3055202A patent/CA3055202A1/en active Pending
- 2018-03-02 CN CN201880025103.XA patent/CN110831961B/zh active Active
- 2018-03-02 EP EP18760420.2A patent/EP3589646A4/en active Pending
- 2018-03-02 SG SG11201907922PA patent/SG11201907922PA/en unknown
- 2018-03-02 SG SG10202001869VA patent/SG10202001869VA/en unknown
-
2023
- 2023-08-11 AU AU2023214349A patent/AU2023214349A1/en active Pending
- 2023-08-30 JP JP2023139792A patent/JP2023164900A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511529A5 (zh) | ||
| US11932698B2 (en) | Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof | |
| US12060394B2 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
| JP2020525536A5 (zh) | ||
| JP2022130485A (ja) | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| US20200399393A1 (en) | Dimeric Antigen Receptors | |
| IL262321B2 (en) | Preparations and methods for selective protein expression | |
| KR20230129983A (ko) | 조작된 세포 요법을 위한 표적화된 사이토카인 구축물 | |
| CA3177394A1 (en) | Method and compositions for cellular immunotherapy | |
| CN111954714A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| TW202023580A (zh) | 使用靶特異性融合蛋白進行ｔｃｒ再程式化之組合物及方法 | |
| US11220535B2 (en) | Anti-BCMA chimeric antigen receptors | |
| US20220251168A1 (en) | Dimeric Antigen Receptors (DAR) that Bind BCMA | |
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| JP2024023497A (ja) | ＴＧＦ－β受容体及び使用方法 | |
| WO2022036224A1 (en) | Chimeric antigen receptor t cells for treating autoimmunity | |
| US20200347148A1 (en) | Methods for enhancing and maintaining car-t cell efficacy | |
| US20240226154A9 (en) | Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same | |
| WO2023133424A2 (en) | Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides | |
| JPWO2021046432A5 (zh) |